Next Phase Newsletter

A venture capital firm headquartered in Western Europe is led by a small, academically focused team located throughout the globe in London, the USA, and Israel. The firm makes, on average, 4-6 investments per year with a total of 20 initial ticket investments via their current fund. The firm invests in pre-clinical companies in early stages, with a sweet spot for Seed and Series A rounds. The firm is open to making investments via any investment vehicle, typically in the form of equity, safe or convertible notes. The firm will invest up to $5-6M. The firm invests globally, with a large number of investments in North America. 
 
The firm invests solely in therapeutics. The firm is focused on “advanced therapeutics”, encompassing anything that is highly targeted such as gene therapy, cell therapy, siRNA, genetic medicine and computational biology. The firm is indication agnostic, with a large interest, however, in oncology. 
 
The firm will co-lead or syndicate rounds, with a preference to co-lead. The firm has no specific team requirements. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A venture capital firm actively invests in pre-seed and seed stage companies. Typical initial size of investment ranges from $1-1.5M. The firm focuses on the following areas: digital economy, climate & environment, health & well-being. The firm is strongly interested in companies based in North America and Latin America. 
 
Historically, the firm has been agnostic towards technology area and indications. That said, the firm is currently interested in exploring opportunities in new modalities and biologics, and expanding their interests in peptide-based therapies and induced proximity therapeutics (i.e. molecular glues, PROTACs). The firm invests mainly in pre-clinical and early clinical therapeutics. The firm actively invests in therapeutics, diagnostics, and life science tools. 
 
The firm seeks to work with exceptional entrepreneurs who are passionate about their work, and is open to working with first-time entrepreneurs. The firm’s investment process starts from an initial meeting and evaluating the opportunity, a decision analysis including the addressed market, life stages assessment, and a final assessment, and if choosing to move forward, proceeding with legal due diligence and signing/execution. To date, the firm has led about 50% of their deals, and following in the other half. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A venture capital firm headquartered in Western Europe is focused on enabling technology within life sciences and healthcare. firm will make initial investments ranging from at a minimum of 1M euro, and will make follow-on investments in total adding up to 5M-7M euro. The firm will invest in Seed-Series B companies. The firm will be launching their new fund in 2025. The firm aims to be a meaningful investor, looking to lead deals, but will also co-lead and can syndicate in certain cases. The firm will generally invest within Western Europe. 
 
The firm will invest in diagnostics, medical devices, and digital health. The firm is not open to investing in therapeutics. The firm is not interested in invasive devices and will not invest in Class 3 and some Class 2 devices. The firm will look at companies with IND approval and in early-clinical stages. 
 
The firm does not have any specific team requirements. The firm considers themselves active, hands-on investors and will typically require a board seat. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A corporate venture arm of a corporation headquartered in Asia with offices in the US is mandated to invest in venture stage companies across several sectors including the Life Sciences. The firm started investing in the Life Sciences in 2012 and has made 20 investments thus far. The firm can allocate up to USD 20 million depending on the stage of the company. The firm can invest globally and is actively seeking new investment opportunities. 
 
In the Life Sciences, the firm is interested in therapeutics, medical devices, diagnostics, and digital health. The firm seeks technologies that are differentiated and address a major unmet medical need. The firm is agnostic to the stage of development and therefore will consider therapeutics in pre-clinical and devices/technology in concept stage. The firm focuses on products that have a clear and fast path to market. Historically, the firm invested in drug discovery, diagnostics for tumors, and devices for COPD and POAG. 
 
The firm is looking for companies with experienced management teams. The firm is willing to both lead and act as a member of a syndicate. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A venture capital firm of a family-owned service provider seeks investments in Seed to Series A/B, with an initial check ranging between 3-7 million Euros. Follow-on investments are possible, and the firm may invest up to 15 million Euros throughout the life cycle. The firm is open to both leading and co-investing. The firm focuses on opportunities in Europe, UK and US. 
 
The firm is interested in early-stage therapeutic technologies. The firm is agnostic regarding modalities and indications, and is open to exploring different types of therapeutic assets. Additionally, the firm has invested in orphan drugs. While there is no strict mandate for the development phases of assets, having at least in-vivo data would generally be preferred. 
 
There are no specific requirements for companies’ management team. 
 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A venture arm of a global pharmaceutical company with a market cap exceeding $11 billion, is actively investing in the early-stage healthcare sector. The firm focuses on pre-seed/seed-stage opportunities, with the initial investment range spanning 0.5-2 million. The firm is interested in opportunities globally with a focus in the US. The firm is open to both leading and co-investing and will consider board seats when leading the round. While the firm is mostly finance driven, the firm is able to bring in the strategic perspective if deemed necessary. 
 
The firm seeks companies with innovative sciences addressing highly unmet needs. The firm is focused on therapeutic, including cell and gene therapy, small molecules, radiopharmaceuticals, CRISPR, and data-driven technologies such as AI-driven drug discovery. The firm is interested in oncology, neurology, and rare diseases. Less invasive diagnostic technologies are also within the scope. The firm mostly works with companies in the preclinical to phase I stages. 
 
The firm focuses on finding promising science backed by strong IP. As an active investor, the firm supports portfolio companies through its extensive network and resources.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A multi-family venture fund based in the US is an active investor in the medical device sector, and is interested in opportunities in the western United States. Initial investments are typically about $150,000 with the potential for follow-on investments totaling $1 million and may be structured as equity or as debt. The firm offers support and expertise to portfolio companies but does not seek a board seat. 
 
The firm is interested in medical technology and lab equipment, including electro-mechanical medical devices, active implantable devices, and surgical instruments. The firm invests only in companies that have already developed a prototype of their product,  filed a patent application and have animal data. 
 
The firm seeks to invest in strong management teams with prior experience in the medical device industry. The firm prefers to make investments with the potential to exit within 3-4 years. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.